Dendritic Cell-based Immunotherapy for Rheumatoid Arthritis: from Bench to Bedside.
- Author:
Md Selim AHMED
1
;
Yong Soo BAE
Author Information
- Publication Type:In Vitro ; Review
- Keywords: Tolerogenic dendritic cell (tolDC); Immunotherapy; Tolerance; Rheumatoid arthritis (RA); Mouse collagen-induced arthritis (CIA); Clinical study; Treg; Limitation; Future
- MeSH: Adaptive Immunity; Antigen-Presenting Cells; Arthritis, Rheumatoid*; Dendritic Cells; Homeostasis; Immune System Diseases; Immune Tolerance; Immunotherapy*; Models, Animal
- From:Immune Network 2016;16(1):44-51
- CountryRepublic of Korea
- Language:English
- Abstract: Dendritic cells (DCs) are professional antigen presenting cells, and play an important role in the induction of antigen-specific adaptive immunity. However, some DC populations are involved in immune regulation and immune tolerance. These DC populations are believed to take part in the control of immune exaggeration and immune disorder, and maintain immune homeostasis in the body. Tolerogenic DCs (tolDCs) can be generated in vitro by genetic or pharmacological modification or by controlling the maturation stages of cytokine-derived DCs. These tolDCs have been investigated for the treatment of rheumatoid arthritis (RA) in experimental animal models. In the last decade, several in vitro and in vivo approaches have been translated into clinical trials. As of 2015, three tolDC trials for RA are on the list of ClinicalTrial.gov (www.clinicaltrials.gov). Other trials for RA are in progress and will be listed soon. In this review, we discuss the evolution of tolDC-based immunotherapy for RA and its limitations and future prospects.
